
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA focuses on neurodegenerative diseases and utilizes proprietary technology to develop innovative therapies targeting protein misfolding, notably through its diverse pipeline, which includes advanced candidates like ACI-7104.056. The upcoming readout from this candidate is expected to provide critical insights, particularly given its previous successes in raising antibodies to pathogenic variants of aSyn by 20 times, which could enhance its therapeutic potential. Additionally, the strategic use of mAbs with titration dosing schemes positions the company favorably in the evolving treatment landscape for Alzheimer's disease, indicating a promising outlook for its therapeutic innovations.
Bears say
AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, indicating significant financial challenges for the clinical-stage biopharmaceutical company. The company operates in a highly competitive field characterized by unpredictable clinical outcomes, regulatory uncertainties, and evolving commercial dynamics that can impact market viability. These factors contribute to an overall negative outlook, as the risks associated with its clinical pipeline may limit investor confidence and hinder financial stability.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares